Vertex highlights kidney pipeline as povetacicept cuts proteinuria 52% in Phase III

Vertex Pharmaceuticals highlights its kidney pipeline as povetacicept reduced proteinuria by 52% in a Phase III trial.

Detected & updated continuously · Source: Nebula